It would have been a great quarter for ultrasound vendor AdvancedTechnology Laboratories. The Bothell, WA, company last week reportedthat revenues climbed 8% for the second quarter, while incometripled over the same period a year ago. Unfortunately,
It would have been a great quarter for ultrasound vendor AdvancedTechnology Laboratories. The Bothell, WA, company last week reportedthat revenues climbed 8% for the second quarter, while incometripled over the same period a year ago.
Unfortunately, ATL was forced to take a whopping $29.6 millionone-time charge in the quarter to pay for a damage award grantedto SRI International in connection with a patent infringementcase the company filed against ATL. A U.S. District Court judgein May assessed ATL $27.9 million in damages in connection withthe case (SCAN 6/5/96). ATL is pursuing an appeal of the decision.
The litigation charge wiped out what would have been a netprofit of $3.5 million. Instead, ATL wound up with a net lossfor the period of $19.2 million, compared with net income of $836,000in the second quarter of last year, when ATL took a one-time chargerelated to its consolidation of Interspec. ATL recorded an incometax benefit for the most recent quarter of $6 million.
ATL's revenues were a bright spot for the company, climbingto $98.6 million, compared with $91.3 million in the same periodof 1995. The company's gross margin improved to 48.4% from 46.6%due to an improved product mix and cost reduction programs.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.